Back to dashboard
All PlansAdministrativeLow impact

[Virginia] Lenalidomide is now available with end‑to‑end REMS support

Anthem BCBS·VA · Oncology, Hematology·Provider Bulletin
Effective date
Not stated
We identified it
May 3, 2026
Days to comply
—

Summary

Lenalidomide, a cancer medication, is now available with end-to-end Risk Evaluation and Mitigation Strategy (REMS) support in Virginia. This change provides enhanced support for the medication's safety monitoring requirements.

Action Required

Action needed
Review current lenalidomide prescribing and billing processes to understand how the new end-to-end REMS support may impact patient care coordination and documentation requirements. Contact Anthem for specific details on how this REMS support affects billing procedures.

Related policy hubs